Medicines pricing system creating ‘false economy’ that drives shortages, says CCA report A report published by the Company Chemists’ Association found that the number of price concessions granted for generic medicines increased by over 740% from 2015 to 2024.…
Manufacturer offers NHS £23m in response to investigation into misleading claims about rival treatment Vifor Pharma has also agreed to write to healthcare professionals to “correct any potentially misleading communications regarding the safety of Monofer and Ferinject”.…
Pfizer and Flynn Pharma fined £69m for ‘excessive’ pricing of epilepsy drug The Competition Appeal Tribunal has upheld the Competition and Markets Authority's 2016 decision that Pfizer and its distributor Flynn “were gouging the market” when the pricing of phenytoin sodium capsules resulted in costs to the NHS increasing from £2m in 2012 to around £50m in 2013.…
NICE may be ‘systematically undervaluing’ medicines for severe conditions, says ABPI The Association of the British Pharmaceutical Industry is urging the government and National Institute for Health and Care Excellence to “show greater flexibility when assessing medicines for severe conditions”.…
Manufacturers repay nearly £600m to NHS in first three months of new voluntary pricing scheme The first repayment of the new scheme was larger than all quarterly payments under VPAS between 2019 and 2022.…
Scottish government publishes prescribing guidance aiming to save millions of pounds The Scottish government's draft guidance sets out a list of 17 products that are of “low clinical value” and 11 products that are of “limited clinical value”.…
Haemophilia treatment first to be recommended by NICE as part of new drug pricing agreement Etranacogene dezaparovovec (Hemgenix; CSL Behring) is also the first medicinal product to enter the Innovative Medicines Fund.…
Drug reimbursement reforms could increase price volatility, warns negotiator Community Pharmacy England said a move to quarterly updating of Category A reimbursement prices could have an "unknown impact" on medicines supply chains.…
Medicine pricing agreement will double annual growth in cost of branded drugs sold to the NHS Under the 'Voluntary scheme for branded medicines pricing, access and growth', the annual allowed rate of growth in sales will rise to 4% by 2027.…
Hydrocortisone manufacturers to be fined almost £130m after tribunal upholds ruling The Competition and Markets Authority said NHS spending on hydrocortisone tablets rose from £0.5m per year to over £80m.…
